Literature DB >> 6431604

In vivo metabolism of human tissue-type plasminogen activator.

T Nilsson, P Wallén, G Mellbring.   

Abstract

The turnover of human tissue-type plasminogen activator (t-PA), purified from cell culture fluids and radiolabelled with 125I, was studied in 2 healthy males. After injection, the plasma radioactivity initially disappeared with a half-life of about 3 min, but after 30 min reached a plateau level which persisted for several hours. The radioactive material had then already been converted to forms soluble in 10% trichloroacetic acid (TCA). Surface counting rates indicated a rapid uptake in the liver during the first 10 min after injection, followed by a rapid release from the liver, beginning already at 25 min, which coincided with the appearance of the TCA-soluble radioactive material. After 18 h, about 80% of the injected dose had already been excreted in the urine. We conclude that, in humans, injected t-PA is rapidly cleared from the circulation, mainly by the liver, and within 30 min metabolized to low molecular weight forms which ultimately (within 1 d) appear in the urine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431604     DOI: 10.1111/j.1600-0609.1984.tb02209.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  15 in total

1.  Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors:  Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

2.  Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

Authors:  D C Rijken; J J Emeis
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

3.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

4.  Characterization of indium-111 labeled recombinant tissue plasminogen activator for the imaging of thrombi.

Authors:  D J Hnatowich; F Virzi; P W Doherty; J Wilson; J Rosa; J E Ansell
Journal:  Eur J Nucl Med       Date:  1987

5.  Kinetic studies on the interaction of streptokinase and other plasminogen activators with plasminogen and fibrin.

Authors:  R Fears; M J Hibbs; R A Smith
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

Review 6.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.

Authors:  E Tsukamoto
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

8.  Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.

Authors:  J I Weitz; M K Cruickshank; B Thong; B Leslie; M N Levine; J Ginsberg; T Eckhardt
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

9.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

Review 10.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.